Paladin gains FDA approval for leishmaniasis drug

03/20/2014 | Reuters

Canadian pharmaceutical firm Paladin Labs received federal approval for its Impavido drug to address leishmaniasis, a parasitic disease transmitted via sand fly bites that is usually acquired when traveling abroad. The drug is to be used in patients 12 and older.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
Minneapolis, MN
In house Compliance Officer
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC